MedTrace Logo

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

NCT00169143 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-23

No results posted yet for this study

Summary

Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international prognostic index (Aa-IPI).

Conditions

  • Untreated CD20-positive Large B-cell Lymphoma

Interventions

DRUG

Rituximab + ACVBP regimen plus Pegfilgrastim

PROCEDURE

Autologous stem cell transplant

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Corinne Haioun, MD · Hôpital Henri Mondor, Créteil, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
61 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169143 on ClinicalTrials.gov